{"organizations": [], "uuid": "aa656f92dec96c6eb1dc46b164aa6fe5fff3b2b1", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-merck-co-says-us-fda-has-set-pdufa/brief-merck-co-says-u-s-fda-has-set-pdufa-date-of-sept-23-2018-idUSASC09Y5R", "country": "US", "domain_rank": 408, "title": "BRIEF-Merck & Co Says U.S. FDA Has Set PDUFA Date Of Sept. 23, 2018", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.969, "site_type": "news", "published": "2018-04-30T19:10:00.000+03:00", "replies_count": 0, "uuid": "aa656f92dec96c6eb1dc46b164aa6fe5fff3b2b1"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-merck-co-says-us-fda-has-set-pdufa/brief-merck-co-says-u-s-fda-has-set-pdufa-date-of-sept-23-2018-idUSASC09Y5R", "ord_in_thread": 0, "title": "BRIEF-Merck & Co Says U.S. FDA Has Set PDUFA Date Of Sept. 23, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-merck & co says u.s. fda", "sentiment": "negative"}, {"name": "merck", "sentiment": "negative"}, {"name": "reuters) - merck & co inc", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "none"}, {"name": "pdufa", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - Merck & Co Inc:\n* FDA GRANTS PRIORITY REVIEW TO MERCK’S SBLA FOR KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH PEMETREXED (ALIMTA®) AND PLATINUM CHEMOTHERAPY BASED ON RESULTS FROM PHASE 3 KEYNOTE-189 TRIAL AS FIRST-LINE TREATMENT OF METASTATIC NONSQUAMOUS NSCLC\n* MERCK & CO INC - U.S. FDA HAS SET A PDUFA DATE OF SEPT. 23, 2018 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-30T19:10:00.000+03:00", "crawled": "2018-05-01T19:50:30.021+03:00", "highlightTitle": ""}